01—Abstract
Summary
Summary of the 8-K filed January 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Colgate-Palmolive reported fourth quarter and full-year 2025 results on January 30, 2026, and the headline is a large non-cash write-down that obscures a steady underlying business.
GAAP diluted EPS fell 25% to $2.63a for the year, and Q4 GAAP EPS was $(0.05), driven by a $794 million after-tax goodwill and intangible impairment tied to the skin health business (primarily Filorga), which management cut after weaker-than-expected performance, particularly in China. On a Base Business (non-GAAP) basis, full-year EPS rose 3% to $3.69 and Q4 EPS rose 4% to $0.95. Full-year net sales grew 1.4% to $20.4 billion, with organic sales also up 1.4%, though a 0.7% drag came from lower private label pet volume.
Q4 organic growth accelerated to 2.2% and net sales rose 5.8%, helped by 3.1 points of favorable FX. Cash generation was strong, with record operating cash flow of $4.2 billionb and free cash flow before dividends of $3.6 billion. The company returned $2.9 billion to shareholders through dividends ($1.8 billion) and buybacks ($1.2 billion).
Base Business operating margin for the year was roughly 21.3%c, down about 40 basis points, while Base Business gross margin fell about 50 basis points to 60.1%, reflecting cost and mix pressures. Management also introduced a new 2030 strategy and guided 2026 to net sales growth of 2% to 6% and organic growth of 1% to 4%, with GAAP EPS growing double digits and Base Business EPS growing low to mid single digits. Management said the operating environment will remain difficult in the near term.
For investors, the key question is whether the impairment marks a one-time reset or signals weakening in the skin health franchise and China. The Base Business numbers show modest but steady earnings growth and healthy cash returns, while the GAAP figures are distorted by the charge. The guidance implies a return to GAAP EPS growth in 2026, but the gap between GAAP and Base Business outlook and the mention of a sluggish category backdrop mean investors should watch whether Q4 organic momentum can be sustained.
02—Key points
Key Highlights
- GAAP diluted EPS fell 25% to $2.63 for FY2025, while Base Business EPS rose 3% to $3.69, with the gap driven by a $794 million after-tax goodwill and intangible impairment tied to skin health (Filorga).
- Q4 2025 GAAP net sales rose 5.8% to $5.23 billion, but organic sales growth was 2.2%, with FX contributing 3.1 points; Latin America grew organically 6.5% and Europe 1.8%, while North America declined 1.8%.
- FY2025 net sales rose 1.4% to $20.38 billion; organic growth was also 1.4%, held back by a 0.7% negative impact from lower private label pet volume.
- Record FY2025 operating cash flow of $4.2 billion and free cash flow before dividends of $3.6 billion, supporting $2.9 billion returned to shareholders via dividends and buybacks.
- Base Business gross margin declined about 50 basis points to 60.1% for FY2025, and Base Business operating margin fell about 40 basis points to 21.3%.
- 2026 guidance calls for net sales growth of 2% to 6% and organic growth of 1% to 4%, including a roughly 20 basis point drag from exiting private label pet food.
- 2026 GAAP EPS guidance calls for double-digit growth, while Base Business EPS guidance is low to mid single digits; management launched a new 2030 strategy focused on growth, innovation, and omni-channel demand generation.
03—Questions
Frequently Asked Questions
Why did GAAP EPS fall so sharply in 2025?
GAAP diluted EPS declined 25% to $2.63 mainly because of a non-cash goodwill and intangible assets impairment of $919 million pre-tax ($794 million after tax) recorded in Q4 2025 related to the skin health business. Management cut its outlook for that business, primarily Filorga, due to slower category growth and weaker-than-expected performance, particularly in China. Excluding this and other non-recurring items, Base Business EPS rose 3% to $3.69.
Is the underlying business growing?
Modestly. Full-year organic sales grew 1.4%, and Q4 organic sales accelerated to 2.2%, with growth in every category led by oral care and pet nutrition excluding private label. Latin America and Africa/Eurasia were the strongest regions in Q4, while North America declined. Management said the difficult operating environment and slow category growth are expected to continue in the near term.
How strong is the company's cash flow and capital return?
Cash flow was strong. Net cash from operations reached a record $4.198 billion for 2025, and free cash flow before dividends was $3.634 billion. The company paid $1.82 billion in dividends and repurchased $1.21 billion of shares, for a total of about $2.9 billion returned to shareholders.
What does 2026 guidance imply for investors?
Management guided to net sales growth of 2% to 6% (including a low-single-digit FX benefit) and organic growth of 1% to 4%. On a GAAP basis, it expects double-digit EPS growth and gross margin expansion. On a Base Business basis, it expects low to mid single-digit EPS growth and gross margin expansion. Advertising spending is expected to rise in both dollars and as a percentage of sales. Guidance assumes current spot FX rates and tariffs announced as of January 28, 2026.
What are the main risks highlighted in the filing?
Key risks include the impairment of the skin health business and its performance in China, slower category growth in many markets, foreign exchange volatility, trade policy and tariffs, geopolitical tensions, and margin pressure (Base Business gross margin fell about 50 basis points in 2025). The company also reported a $65 million ERISA litigation charge in 2025 and continues restructuring under its Strategic Growth and Productivity Program.
04—Continue